Exposure–Response Analysis for Aripiprazole Once‐Monthly in Patients Diagnosed With Bipolar I Disorder
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1580 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Xiaofeng Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacometrics, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA. Hauptthemen laut MEDLINE: Aripiprazole, Bipolar Disorder, Antipsychotic Agents, Models, Biological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aripiprazole once‐monthly (AOM) is approved for the maintenance monotherapy treatment of bipolar I disorder (BP‐I) in adults. A previously developed population pharmacokinetic model was validated by applying it to data from patients diagnosed with BP‐I. The model was then used to generate aripiprazole exposures for an exposure‐response model intended to describe the relationship between aripiprazole exposure and time to recurrence of any mood episode in patients with BP‐I. The BP‐I data were best described by a continuous model in which higher aripiprazole exposure was associated with a lower risk of recurrence. For each 1 ng/mL increase in aripiprazole plasma concentration, the predicted hazard for recurrence decreased by 0.34%. An aripiprazole plasma concentration of 95 ng/mL (clinically relevant in schizophrenia) was tested in a separate categorical model and was a significant predictor of time to recurrence ( P = .0270), with a 36% (1.55‐fold) decrease in the predicted risk of recurrence with an aripiprazole concentration of ≥95 versus
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacometrics, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.
- Simulations Plus, Inc., Clinical Pharmacology and Pharmacometrics Business Unit, Buffalo, NY, USA.
- Discovery Research, Early Phase and Translational Medicine, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.
- Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.
- Clinical & Quantitative Pharmacology, H. Lundbeck A/S, Valby, Denmark.
- Global Medical Affairs, H. Lundbeck A/S, Valby, Denmark.
Zitieren
APA
Wang, X., Phillips, L., Harlin, M., Bell Lynum, K. S., Larsen, F., Such, P., Madera-McDonough, J., Yildirim, M., Procyshyn, R. M., Chepke, C., & Passarell, J. (2025). Exposure–Response Analysis for Aripiprazole Once‐Monthly in Patients Diagnosed With Bipolar I Disorder. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1580
Vancouver
Wang X, Phillips L, Harlin M, Bell Lynum KS, Larsen F, Such P, et al. Exposure–Response Analysis for Aripiprazole Once‐Monthly in Patients Diagnosed With Bipolar I Disorder. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1580
BibTeX
@article{Wang2025,
author = {Wang, Xiaofeng and Phillips, Luann and Harlin, Matthew and Bell Lynum, Karimah S and Larsen, Frank and Such, Pedro and Madera-McDonough, Jessica and Yildirim, Murat and Procyshyn, Ric M and Chepke, Craig and Passarell, Julie},
title = {Exposure–Response Analysis for Aripiprazole Once‐Monthly in Patients Diagnosed With Bipolar I Disorder},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1580}
}
EUVIMED